Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026GlobeNewsWire · Oct 12, 2026
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetesGuruFocus · Sep 30, 2026
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparisonGuruFocus · Sep 29, 2026
Apnimed Announces Pricing of Upsized Initial Public OfferingGuruFocus · Jul 30, 2026ProSomnus, Inc. develops and provides specialized oral appliance therapy solutions crafted to alleviate obstructive sleep apnea (OSA). This enterprise, which originated in 2016, maintains its headquarters in Pleasanton, California.